An Acupuncture Study for Cancer Survivors With Joint Pain
Researching the Implementation of Acupuncture for Chronic Musculoskeletal Pain in Diverse Underserved Cancer Survivors (ReIMAGINE)
1 other identifier
interventional
60
1 country
2
Brief Summary
The purpose of this study is to see whether acupuncture is a practical (feasible) treatment for cancer survivors with joint pain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2025
Longer than P75 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 31, 2025
CompletedFirst Submitted
Initial submission to the registry
February 3, 2025
CompletedFirst Posted
Study publicly available on registry
February 7, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2028
October 10, 2025
October 1, 2025
3.4 years
February 3, 2025
October 9, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Study feasibility as measured by rates of enrollment
The primary purpose of this study is to determine the feasibility of studying an acupuncture intervention for chronic musculoskeletal pain in racially/ethnically diverse, community-based cancer survivors.
1 year
Study Arms (2)
Acupuncture
EXPERIMENTALParticipants will receive 10 weekly acupuncture treatments over 10 weeks.
Usual Care
NO INTERVENTIONParticipants will receive standard medical care, including pain medications and other treatments
Interventions
Acupuncture is a non-pharmacological intervention that does not involve the use of any therapeutic agents or devices. Participants will receive 10 weekly treatments over 10 weeks.
Eligibility Criteria
You may qualify if:
- English- or Spanish-speaking adults
- Non white or Hispanic women with a prior cancer diagnosis
- Stable oncological disease or no evidence oncological of disease per clinical documentation or clinician assessment
- Worst pain rated ≥4 on a 0-10 scale in the preceding week
- ≥15 days with pain in the past 30 days
- Pain lasting ≥1 month
- Willing and able to complete questionnaires and other study activities
- Willing and able to provide informed consent for the trial
You may not qualify if:
- Completed active treatment (chemotherapy, surgery, radiation, transplantation) \<4 weeks prior to study
- Maintenance therapies are allowed
- Pain attributed to inflammatory arthritis (e.g., rheumatoid arthritis, gout)
- Other non-musculoskeletal pain syndromes (eg, headache, visceral abdominal pain, neuropathic pain) can be present as comorbid conditions if the patient reports musculoskeletal pain as the primary source of pain
- Procedures involving affected joints within the last month or planned in the next 14 weeks
- Acupuncture use for pain in the past three months
- Implanted electronic device (e.g., pacemaker)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Memorial Sloan Kettering Cancer Center (All protocol activites)
New York, New York, 10065, United States
Jamaica Hospital Medical Center
Richmond Hill, New York, 11418, United States
Related Links
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kevin Liou, MD
Memorial Sloan Kettering Cancer Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 3, 2025
First Posted
February 7, 2025
Study Start
January 31, 2025
Primary Completion (Estimated)
June 30, 2028
Study Completion (Estimated)
June 30, 2028
Last Updated
October 10, 2025
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will share
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.